Recombinant insulin aspart biosimilar (Yichang Hec Changjiang Pharmaceutical)

门冬胰岛素生物类似药 (宜昌东阳光长江药业)

Report date: 2026/05/13 20:02:10

Base Information

Drug NameRecombinant insulin aspart biosimilar (Yichang Hec Changjiang Pharmaceutical)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsDiabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus
Original Approved Country/TerritoryMainland China
Original Approved Date2022/10/11
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesYichang Hec Changjiang Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesYichang Hec Changjiang Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A